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Background/aim: Malnutrition is an important and commonly seen prognostic factor in patients with cirrhosis. The diagnosis of
malnutrition in cirrhosis patients may be challenging, and an easily measured and widely usable marker is lacking. Prealbumin,
however, is an easily measured marker. In the current study we measured prealbumin levels in cirrhotic patients with no clinically
apparent malnutrition and used it as a malnutrition marker. Another aim of this study was to evaluate the effect of nutritional support
on patient with low prealbumin levels.
Materials and methods: Fifty-two patients with Child A and Child B cirrhosis were selected for the study. Prealbumin levels were
studied, and Child and MELD scores were calculated. Patients with prealbumin levels ˂180 mg/L were considered to have malnutrition,
and two different types of nutritional products were given to these patients. The patients given nutritional support were investigated a
month later, and parameters were compared.
Results: According to the prealbumin threshold of 180 mg/L, malnutrition frequencies were 59.3% for Child A and 95% for Child B
cirrhosis. After the provision of nutritional support statistically significant improvements in albumin and INR levels were detected. In
addition, the MELD score decreased; however, it was not statistically significant (P: 0.088). A statistically significant decrease in the
MELD score was only obtained in patients with Child B cirrhosis (P: 0.033). When the oral replacement therapies were investigated
separately, a statistically significant decrease in MELD scores was detected with product 1 (P: 0.043).
Conclusion: Prealbumin can be used as an easily measured parameter for earlier detection of malnutrition in patients with cirrhosis
and without clinically apparent malnutrition. Oral nutritional support, especially with products containing relatively high carbohydrate
levels and low protein, may have a favorable effect on MELD scores.
Key words: Malnutrition, cirrhosis, prealbumin, nutritional support, MELD score

1. Introduction
Malnutrition is commonly seen in patients with cirrhosis.
Most trials show that 60%–100% of patients with advanced
cirrhosis have malnutrition [1–4]. Malnutrition may even
be seen in patients with Child A cirrhosis, at a frequency
of 25% to 46% [1,4]. Malnutrition is a poor prognostic
factor in cirrhosis and is associated with lower survival
and higher complication rates [5–9]. The correction of
malnutrition may improve mortality, increase quality of
life, decrease complications, and prepare patients for liver
transplantation [6]. Malnutrition in patients with cirrhosis
results from a variety of factors, including inadequate
intake, poor-quality diet, malabsorption, maldigestion,
altered macronutrient metabolism, and a hypermetabolic
state [10].

Prealbumin is an easily measured marker for predicting
protein malnutrition [11,12]. It can be synthesized by the
liver up until advanced cirrhosis, and fluid retention has
no effect on prealbumin [12]. After adequate nutrition
is provided, prealbumin levels increase rapidly and may
come to within normal range in 8 days [11]. To date,
the use of prealbumin in determining malnutrition in
patients with cirrhosis was not sufficiently investigated.
Nutritional support with enteral or parenteral
nutrients may be beneficial in patients with cirrhosis.
The European Association for the Study of the Liver
suggests nutritional counseling in cirrhotic patients
with malnutrition [13]. The optimal daily energy intake
should be higher than 35 kcal/kg with 1.2–1.5 g/kg of
protein intake [11,14].

* Correspondence: huseyinko@yahoo.com

398

This work is licensed under a Creative Commons Attribution 4.0 International License.

DAĞ et al. / Turk J Med Sci
The aim of this study was to evaluate prealbumin as
an early marker in predicting malnutrition in Child A and
Child B cirrhosis without clinically evident malnutrition.
Another aim was to evaluate the effect of nutritional
support with oral supplements on clinical and laboratory
findings in these patients.
2. Materials and methods
This study was performed prospectively at Ankara
Education and Research Hospital between November 2014
and May 2015. Patients who had compensated cirrhosis
with different etiologies and were managed as outpatients
were included in the study. The diagnosis of cirrhosis
was based on a combination of clinical, laboratory, and
radiologic findings, and liver biopsy was performed if the
diagnosis was indefinite. Patients who were under 18 years
old; who had sepsis, major psychiatric diseases, cancer
diagnosis, kidney failure, alcohol abuse, decompensated
cirrhosis, hepatic encephalopathy, Child C cirrhosis, or
fulminant hepatic failure were excluded from the study.
Patients whose body mass index (BMI) was lower than
18.5 kg/m2, and patients who were taking warfarin were
not included in the study. At the beginning of the study,
demographic features of the patients were recorded, and
laboratory examinations were performed. Total white blood
cell (WBC), hemoglobin (Hb), hematocrit (HTc), and
platelet (PLT) levels were determined in samples obtained
from peripheral blood; serum aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALP), gama-glutamil transferase (GGT),
albumin, total protein, sodium, potassium, calcium, blood
urea nitrogen (BUN), creatinine, C-reactive protein (CRP),
international normalized ratio (INR), 25 hydroxyvitamin
D, vitamin B12, ferritin, thyroid-stimulating hormone
(TSH), prealbumin, and alpha-fetoprotein (AFP) levels
were examined with fully automated devices. MELD and
Child–Pugh scores were calculated. Body mass index was
calculated by dividing weight in kilograms by the square of
the height in meters.
None of the patients involved in this study had clinically
evident malnutrition. Patients whose prealbumin levels
were ˂180 mg/L were considered to have malnutrition;
these patients received oral supplementation with
standard products. The patients were randomly divided
into two groups, and two different oral supplements were
used. Product 1 contained 1.5% kcal/mL, 16.7% protein,
53.8% carbohydrate, and 29.5% fat. Product 2 contained
1.5% kcal/mL, 22.1% protein, 47% carbohydrate, and
28.8% fat with calcium β-hydroxy-β-methylbutyrate,
fructooligosaccharides, and vitamin D. Both supplements
were taken at 220 mL, three times a day. After 1 month
of oral supplement therapy the patients were called
for control, and the same laboratory parameters were
performed and body weight was assessed.

The local medical ethics committee approved the study
design and methods, and all patients provided written
informed consent prior to participating in the study
(medical ethics committee approval date: 05.11.2014;
number: 4700).
All statistical analyses were performed with SPSS 16.0
(IBM Co., Chicago, USA) software. The Kolmogorov–
Smirnov test was used to determine the normality of the
variables. Independent sample t-test, The Kruskal–Wallis
test, and chi-square test of independence were used to
determine the differences in variables. A paired sample
t-test was used to compare variables before and after oral
supplement therapy. Pearson’s correlation analysis was
used to identify the correlation between parameters. P
values of less than 0.05 were considered significant.
3. Results
Patients admitted to our gastroenterology and internal
medicine clinic between November 2014 and May 2015
were included in this study. After exclusions, 32 patients
with Child A cirrhosis and 20 patients with Child B cirrhosis
were included for evaluation. The sociodemographic
features and laboratory parameters at the beginning of the
study are summarized in Table 1.
The etiology of cirrhosis was hepatitis B in 22 patients
(42.3%), hepatitis C in 7 patients (13.5%), alcohol in 3
patients (5.8%), autoimmune hepatitis in one patient
(1.9%), and nonalcoholic steatohepatitis in one patient
(1.9%). Cryptogenic cirrhosis was present in 18 patients
(34.6%).
Among the 52 patients, 38 patients had low prealbumin
levels (73%). The proportions of malnourished patients
(determined as low prealbumin levels) were 59.3% and
95% in patients with Child A and Child B cirrhosis,
respectively. Patients with low prealbumin levels received
oral nutrition therapy with oral supplements. Thirty-eight
patients received oral supplements; 24 patients continued
to follow-up and receive their oral supplements. Among
these patients, 13 had Child A cirrhosis, and 11 had Child
B cirrhosis. After 1 month of oral supplement therapy
the patients were reevaluated. The laboratory parameters,
Child and MELD scores, and weight values before and
after therapy are given in Table 2. Statistically significant
improvement was detected in INR and albumin values. The
same variables were compared for patients with Child A
and Child B cirrhosis separately (Table 3). No statistically
significant change was detected in patients with Child A
cirrhosis, but statistically significant increases in albumin
and statistically significant decreases in INR and MELD
scores were detected in patients with Child B cirrhosis.
Eleven of the patients received product 1, and 13
patients took product 2 as an oral supplement. The patients
were evaluated separately for product 1 and product 2,
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Table 1. Sociodemographic features of patients with Child A cirrhosis and Child B cirrhosis.
Child A

Child B

P

Sex (male/female)

24/8

11/9

0.224

Age, mean (years)

59.65 ± 2.43

62 ± 3.65

0.57

Height, mean (m)

166.30 ± 1.75

161.58 ± 3.36

0.54

Weight, mean (kg)

82 ± 3

75.41 ± 9

0.072

BMI, mean (kg/m2)

28.80 ± 5.45

27.19 ± 10.56

0.052

Disease duration (months)

29.26 ± 10.37

53.25 ± 18.33

0.269

Hb (g/dL)

13.46 ± 1.87

11.43 ± 3.07

0.004

PLT

140968.8 ± 73120

119650 ± 68332

0.293

INR

1.10 ± 0.13

1.34 ± 0.23

0.001

Albumin (g/dL)

4.09 ± 0.36

2.98 ± 0.44

0.001

Total bilirubin (mg/dL)

0.98 ± 0.57

1.45 ± 0.65

0.009

AST (U/L)

39.40 ± 18.60

74.00 ± 48.34

0.001

ALT (U/L)

114.62 ± 114.62

151.55 ± 74.79

0.027

25 OH vit D (µg/L)

19.22 ± 12.96

9.93 ± 6.26

0.001

Vit B12 (pg/mL)

343.71 ± 275.32

603.45 ± 342.37

0.004

Prealbumine (mg/L)

170.90 ± 49.06

86.31 ± 41.10

0.001

BMI: Body mass index, Hb: hemoglobin, PLT: platelets, AST: aspartate aminotransferase, ALT:
alanine aminotransferase, 25 OH vit D: 25-hydroxyvitamin D.
Table 2. Laboratory parameters, weight values, and Child and MELD scores in
patients before and after nutritional support with both oral supplements.
Before therapy

After therapy

P

Weight, mean (kg)

79.83 ± 24.11

80.47 ± 24.43

0.334

BMI, mean(kg/m2)

29.06 ± 10.00

29.28 ± 10.06

0.373

Hb (g/dL)

13.05 ± 2.49

13.20 ± 2.36

0.666

PLT

108540 ± 62205

97750 ± 55401

0.088

INR

1.28 ± 0.24

1.18 ± 0.20

0.012

Albumin (g/dL)

3.58 ± 0.55

3.78 ± 0.60

0.025

T bilirubin (mg/dL)

1.37 ± 0.63

1.40 ± 0.78

0.741

AST (U/L)

59.04 ± 33.01

51.87 ± 27.09

0.307

ALT (U/L)

51 ± 33.89

44.37 ± 28.37

0.257

Prealbumin (mg/L)

111.62 ± 42.26

122.43 ± 46.20

0.118

Child Score

6.33 ± 1.40

6.17 ± 1.24

0.588

MELD score

10.17 ± 3.25

9.50 ± 2.87

0.088

BMI: Body mass index, Hb: hemoglobin, PLT: platelets, AST: aspartate
aminotransferase, ALT: alanine aminotransferase.

and variables before and after therapy are summarized in
Table 4.
After therapy, prealbumin levels increased to normal
levels in only 4 patients. All of these patients had Child A
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cirrhosis; none of the patients with Child B cirrhosis had
normal prealbumin levels after therapy. Because of the
low number with normal prealbumin levels after therapy,
statistical analysis was not performed between patients with
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Table 3. Laboratory parameters, weight values, and Child and MELD scores in patients before and after nutritional support with both
oral supplements for patients with Child A cirrhosis and Child B cirrhosis, separately.
Child A

Child B

Before therapy

After therapy

P

Before therapy

After therapy

P

Weight

83.85 ± 14.21

83.54 ± 14.54

0.746

75.09 ± 32.40

76.84 ± 33.05

0.052

BMI

30.19 ± 14.54

30.08 ± 5.06

0.753

27.71 ± 13.99

28.33 ± 14.15

0.056

Hb (g/dL)

14.22 ± 1.02

13.99 ± 1.88

0.659

11.68 ± 3.02

12.25 ± 2.59

0.167

PLT

126615 ± 68870

112307 ± 66637

0.190

87181 ± 47767

80545 ± 33610

0.258

INR

1.12 ± 0.12

1.08 ± 0.12

0.081

1.46 ± 0.20

1.30 ± 0.21

0.037

Albumin (g/dL)

4.00 ± 0.32

4.07 ± 0.52

0.501

3.08 ± 0.25

3.44 ± 0.51

0.020

T bilirubin (mg/dL)

1.02 ± 0.49

1.07 ± 0.66

0.564

1.79 ± 0.53

1.79 ± 0.76

0.981

AST (U/L)

46.77 ± 19.66

43.54 ± 16.12

0.444

73.54 ± 40.19

61.73 ± 34.34

0.432

ALT (U/L)

47.46 ± 26.38

39.77 ± 16.93

0.266

55.18 ± 42.08

49.82 ± 38.05

0.606

Prealbumin (mg/L)

140.45 ± 26.29

145.35 ± 47.95

0.628

77.54 ± 30.32

95.35 ± 25.69

0.068

Child Score

5.23 ± 0.44

5.31 ± 0.48

0.337

7.64 ± 0.92

7.18 ± 1.08

0.138

MELD score

7.92 ± 1.98

8.00 ± 2.38

0.829

12.82 ± 2.32

11.28 ± 2.41

0.033

BMI: Body mass index, Hb: hemoglobin, PLT: platelets, AST: aspartate aminotransferase, ALT: alanine aminotransferase, 25 OH vit D:
25-hydroxyvitamin D.
Table 4. Laboratory parameters, weight values, and Child and MELD scores in patients before and after nutritional support with each
oral supplement.
Product 1

Product 2

Before therapy

After therapy

P

Before therapy

After therapy

P

Weight

76.82 ± 16.63

76.94 ± 16.06

0.892

82.38 ± 29.47

83.46 ± 30.13

0.286

BMI

28.14 ± 6.74

28.15 ± 5.27

0.968

29.84 ± 12.77

30.23 ± 12.99

0.280

Hb (g/dL)

13.18 ± 2.17

12.47 ± 2.45

0.163

12.95 ± 2.81

13.81 ± 2.18

0.029

PLT

115545 ± 66643

107363 ± 72212

0.237

102615 ± 60271

89615 ± 37160

0.216

INR

1.28 ± 0.28

1.14 ± 0.16

0.012

1.28 ± 0.21

1.22 ± 0.22

0.259

Albumin (g/dL)

3.60 ± 0.52

3.61 ± 0.59

0.931

3.56 ± 0.59

3.93 ± 0.59

0.002

T bilirubin (mg/dL)

1.43 ± 0.67

1.54 ± 1.03

0.420

1.33 ± 0.63

1.28 ± 0.50

0.580

AST (U/L)

49.81 ± 17.88

53.36 ± 34.42

0.618

66.85 ± 40.97

50.51 ± 20.38

0.161

ALT (U/L)

40.82 ± 19.16

42.36 ± 28.59

0.808

59.62 ± 41.47

46.08 ± 29.24

0.155

Prealbumin (mg/L)

112.67 ± 46.68

111.15 ± 42.34

0.860

110.72 ± 40.06

131.97 ± 48.81

0.043

Child Score

6.18 ± 1.40

6.27 ± 1.56

0.588

6.46 ± 1.45

6.08 ± 0.95

0.096

MELD score

10.27 ± 3.55

9.36 ± 3.47

0.043

10.08 ± 3.12

9.62 ± 2.39

0.468

BMI: Body mass index, Hb: hemoglobin, PLT: platelets, AST: aspartate aminotransferase, ALT: alanine aminotransferase, 25 OH vit D:
25-hydroxyvitamin D.

and without normal prealbumin levels after therapy. Among
the patients, 15 had an increase in prealbumin levels, whereas
the prealbumin levels of 9 patients decreased. When patients
with and without prealbumin increases were compared,

there was no difference in laboratory parameters between
the two groups, with the exception of prealbumin, which
was lower in patients who had an increase in prealbumin
levels (99.42 ± 45.77 vs. 131.94 ± 26.91, P: 0.039).
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4. Discussion
Malnutrition is a commonly seen and poor prognostic
factor in patients with cirrhosis [1,5]. It is associated with
higher complication rates and lower survival in patients with
cirrhosis [5–9]. It is important to recognize malnutrition in
such patients. However, detecting malnutrition in patients
with cirrhosis is not always easy due to the presence of
ascites and fluid retention. Body mass index alone may not
be sufficient for detecting malnutrition in patients with
cirrhosis. Cross-sectional imaging, like CT, allows the
direct quantification of muscle mass and may be used for
the assessment of malnutrition [15,16]. CT imaging may
help to diagnose malnutrition in cirrhosis, but its routine
use is limited in clinical practice because of cost, time, and
radiation exposure [13]. Anthropometry, DEXA, and BIA
are alternative diagnostic methods for malnutrition [13].
Anthropometric evaluation, DEXA, and BIA also have
limitations for the detection of malnutrition. For these
reasons an easily accessible diagnostic marker for the
prediction of malnutrition is needed.
Prealbumin is an easily measured marker for protein
malnutrition. The use of prealbumin for detecting
malnutrition in patients with cirrhosis has not been widely
investigated. Our study evaluated serum prealbumin
levels for the diagnosis of malnutrition in patients with no
clinically apparent malnutrition. The aim of this approach is
to detect malnutrition in the early phases, especially before
clinical findings appear. The frequency of malnutrition,
defined as low prealbumin levels, was 73% in our study
population. Because our study population contained only
compensated cirrhotic patients with no clinically apparent
malnutrition, these results show that malnutrition is
much more common than predicted. Although the use
of prealbumin for detecting malnutrition in cirrhotic
patients is not well validated, the fact that prealbumin can
be synthesized by the liver up until advanced cirrhosis [12]
indicates that it could be used as a malnutrition marker
in compensated cirrhosis. The easy use and low expense
of prealbumin could make it a useful malnutrition marker
in patients with early cirrhosis and without clinically
apparent malnutrition.
Oral intake of food is the preferred way to meet
nutritional requirements; however, this intake may be
insufficient in cirrhotic patients [14]. Nutritional support
with oral supplements may provide alternative nutrition
in patients with malnutrition and cirrhosis. It has been
shown that oral supplements are effective in hospitalized
patients [15]. The effect of oral supplements on the natural
history of cirrhosis is not well established, and a limited
number of studies have been published to date. Hirsch
et al. showed that nutritional supplementation reduces
hospitalization for complications in patients with alcoholic
cirrhosis, but they could not show any benefit in liver
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function parameters after 1 year of nutritional support
[17]. It has been shown that enteral nutrition has favorable
effects in severely malnourished cirrhotic patients [18]
and in patients with alcoholic liver disease [19]. However,
other studies showed no benefit of enteral nutrition in
liver diseases [20,21]. Our study is different from these
trials, because none of these studies included cirrhotic
outpatients without clinically significant malnutrition.
Another difference is that our study population consisted
of patients with cirrhosis of different etiologies. The
aforementioned studies included patients with alcoholic
liver diseases [18,20,21]; in our study alcohol was the
etiology for cirrhosis in only a minority of patients.
To the best of our knowledge the effect of nutritional
support with oral supplements in cirrhotic patients with
no clinically apparent malnutrition has not been studied,
and we evaluated two different oral supplement products
in this study population. Patients, whose prealbumin
levels were ˂180 mg/L received two different types of oral
supplementation after randomization. The first product
contained more carbohydrates, whereas the second
product contained more protein and included calcium
β-hydroxy-β-methylbutyrate,
fructooligosaccharides,
and vitamin D. The European Association for the Study
of the Liver suggests nutritional counseling in cirrhotic
patients with malnutrition [13]. The optimal daily energy
intake should be higher than 35 kcal/kg with 1.2–1.5 g/
kg of protein intake in 3 main meals and 3 snacks [11,14].
According to this suggestion the goal for calorie intake
was 35 kcal per kg weight. After 1 month with oral
supplementation statistically significant improvement
in albumin and INR levels were obtained. After therapy
the mean Child and MELD scores decreased; however,
statistical significance could not be achieved. Significant
decreases may be achieved with a larger study population
and longer duration of oral supplement support. A
statistically significant decrease in MELD scores was
achieved in patients with Child B cirrhosis. This shows
that oral nutritional support is effective in patients with
Child B cirrhosis and no clinically apparent malnutrition.
When the products were evaluated separately,
significant increases in prealbumin and albumin levels were
achieved with product 2, and significant improvement of
MELD scores and INR levels were detected with product
1. These data show that higher levels of protein in the oral
supplements may improve prealbumin and albumin levels,
but this has no favorable effect on MELD scores. The exact
mechanism of this discrepancy is unknown, but these
findings suggest that the decrease in MELD scores is not
due to the increase in prealbumin levels. The positive effect
of product 1 on MELD scores shows that calories derived
from carbohydrates should comprise at least 50% of total
calorie intake. Our study also showed that adding calcium
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β-hydroxy-β-methylbutyrate, fructooligosaccharides, and
vitamin D has no favorable effect over calorie support
alone. Similarly, a recently published metaanalysis does
not show any benefit of vitamin D supplementation on
NAFLD treatment [22].
The current study has limitations. The low number
of patients in our study population is a major limitation.
In addition, we provided 1 month of nutritional support,
but a longer duration of supplementation may be more
effective. With a higher number of study participants
and increased duration of nutritional support the
differences detected in MELD and Child scores may reach
statistically significant values. In the current study we used
prealbumin as a predictor for malnutrition in patients with
no clinically apparent malnutrition. The collection of CT,
DEXA, or BIA values at the beginning of the study and a
comparison of these values with prealbumin levels would
be valuable; however, the routine use of these methods
is not recommended, and could include ethical issues.
However, these limitations do not hinder the results of the
study. We showed for the first time that oral nutritional
support improves MELD scores in a group of patients with
cirrhosis and without clinically apparent malnutrition,

especially in patients with Child B cirrhosis. We suggest
that prealbumin levels may be used as an early indicator of
malnutrition, and patients with low prealbumin levels may
benefit from oral nutritional support.
There is a strong association between cirrhosis and
malnutrition. Prealbumin levels may be helpful for
detecting malnutrition in cirrhotic patients who have no
clinically apparent malnutrition. Ease of measurement and
low cost are advantages of prealbumin. Oral nutritional
support showed some beneficial effects in patients with
low prealbumin levels. An INR decrease and albumin
increase was obtained in the study population as a whole,
and a decrease in MELD scores was achieved in patients
with Child B cirrhosis. Different results were achieved
with two different products, and a statistically significant
decrease in MELD score was obtained with product 1.
Product 1 contained 1.5% kcal/mL: 16.7% protein, 53.8%
carbohydrate, and 29.5% fat. More significant results may
be found with higher numbers of study participants and
nutritional support of longer duration.
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